BeOne Medicines (NASDAQ:ONC) Receives "Outperform" Rating from Royal Bank Of Canada

BeOne Medicines (NASDAQ:ONC - Get Free Report)'s stock had its "outperform" rating restated by research analysts at Royal Bank Of Canada in a research report issued on Friday,Benzinga reports. They presently have a $311.00 price objective on the stock. Royal Bank Of Canada's price target points to a potential upside of 22.21% from the stock's previous close.

Several other research firms have also recently weighed in on ONC. Bank of America upgraded BeOne Medicines from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Guggenheim raised their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. boosted their price objective on shares of BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, April 21st. Finally, TD Securities restated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a report on Thursday, April 24th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $319.00.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $254.49 on Friday. The company's 50-day moving average price is $247.69. The stock has a market cap of $27.89 billion, a P/E ratio of -68.41 and a beta of 0.30. BeOne Medicines has a one year low of $141.31 and a one year high of $287.88. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. As a group, research analysts predict that BeOne Medicines will post -5.82 earnings per share for the current fiscal year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, COO Xiaobin Wu sold 51,921 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Chan Henry Lee sold 422 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $266.50, for a total value of $112,463.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 203,452 shares of company stock valued at $51,856,379. Company insiders own 6.62% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.